May 1, 2018
The Japan arm of US Merck on April 27 filed for approval of its anti-PD-1 antibody Keytruda (pembrolizumab) in combination with chemotherapy for the frontline treatment of non-small cell lung cancer (NSCLC) without PD-L1 expression cutoff. More specifically, MSD K.K...read more